Thomas Wilder Sells 186 Shares of Penumbra (NYSE:PEN) Stock

Penumbra, Inc. (NYSE:PEN) Director Thomas Wilder sold 186 shares of the firm’s stock in a transaction dated Wednesday, October 1st. The stock was sold at an average price of $253.93, for a total value of $47,230.98. Following the transaction, the director directly owned 186 shares in the company, valued at approximately $47,230.98. This represents a 50.00% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Thomas Wilder also recently made the following trade(s):

• On Tuesday, August 12th, Thomas Wilder sold 372 shares of Penumbra stock. The shares were sold at an average price of $240.16, for a total value of $89,339.52.

Penumbra Trading Up 1.0%

Shares of PEN stock opened at $256.05 on Monday. The company has a market capitalization of $9.99 billion, a P/E ratio of 68.10, a price-to-earnings-growth ratio of 2.31 and a beta of 0.41. The company has a current ratio of 6.75, a quick ratio of 4.04 and a debt-to-equity ratio of 0.02. The business’s 50 day moving average is $257.64 and its two-hundred day moving average is $262.72. Penumbra, Inc. has a twelve month low of $190.08 and a twelve month high of $310.00.

Penumbra (NYSE:PEN) last released its quarterly earnings results on Tuesday, July 29th. The company reported $0.86 EPS for the quarter, topping the consensus estimate of $0.81 by $0.05. Penumbra had a return on equity of 11.55% and a net margin of 11.54%.The business had revenue of $339.46 million during the quarter, compared to analysts’ expectations of $327.37 million. During the same quarter in the prior year, the business earned $0.64 earnings per share. The company’s quarterly revenue was up 13.4% compared to the same quarter last year. Penumbra has set its FY 2025 guidance at EPS. Equities analysts forecast that Penumbra, Inc. will post 3.67 EPS for the current year.

Wall Street Analyst Weigh In

PEN has been the topic of a number of recent analyst reports. Robert W. Baird boosted their price target on shares of Penumbra from $283.00 to $285.00 and gave the stock an “outperform” rating in a research note on Wednesday, July 30th. Canaccord Genuity Group set a $350.00 target price on Penumbra and gave the stock a “buy” rating in a research report on Wednesday, July 30th. Weiss Ratings reissued a “hold (c)” rating on shares of Penumbra in a research note on Saturday, September 27th. William Blair upgraded Penumbra to a “strong-buy” rating in a research note on Friday, July 18th. Finally, Wells Fargo & Company set a $290.00 price objective on Penumbra in a research report on Wednesday. One investment analyst has rated the stock with a Strong Buy rating, thirteen have given a Buy rating and four have issued a Hold rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $302.93.

Hedge Funds Weigh In On Penumbra

Hedge funds and other institutional investors have recently bought and sold shares of the company. Synergy Investment Management LLC purchased a new stake in Penumbra during the first quarter worth $27,000. First Horizon Advisors Inc. raised its stake in shares of Penumbra by 404.8% during the 1st quarter. First Horizon Advisors Inc. now owns 106 shares of the company’s stock worth $28,000 after buying an additional 85 shares during the last quarter. Newbridge Financial Services Group Inc. purchased a new stake in shares of Penumbra in the 2nd quarter worth about $30,000. Parkside Financial Bank & Trust grew its stake in Penumbra by 70.2% in the 2nd quarter. Parkside Financial Bank & Trust now owns 160 shares of the company’s stock valued at $41,000 after acquiring an additional 66 shares during the last quarter. Finally, AlphaQuest LLC purchased a new position in Penumbra during the 1st quarter valued at about $66,000. 88.88% of the stock is owned by institutional investors and hedge funds.

About Penumbra

Penumbra, Inc, together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. The company offers peripheral products, including the Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombectomy system; and CAT RX.